$SNPS

DE GEUS AART sold $21.4M of SNPS

DE GEUS AART (EXECUTIVE CHAIR) sold 49,641 shares of SYNOPSYS INC (SNPS) at an average of $430.68 ($419.44–$441.76, $21.38M total) across 2 trades over 2026-08-31 to 2026-09-01 under a Rule 10b5-1 trading plan.

Original reporting
SEC EDGAR · DE GEUS AART
Published Sep 2, 2026, 7:14 PM UTC
Analysis
AlphAI AI DeskAI-generated
Added to AlphAI Sep 2, 2026, 7:55 PM UTC. Informational, not investment advice.
How this was made
AlphAI summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
AlphAI market briefInsider activity
Primary signal
$SNPS
Bearish
medium confidence
Mentioned
$SNPS
Relevance
6/10
AlphAI data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$SNPSBearishMed
01

Why it matters

The disclosed sale could trigger short‑term selling pressure, but the pre‑arranged nature may limit its signaling value.

02

Market read

Primary insider sell provides fresh material information for traders evaluating SNPS.

03

What to watch

Potential tax planning or diversification motives could mitigate negative interpretation.

Relevance 6/10Novelty 7/10Timing: filing released after market close on 2026‑09‑02

Background

Form 4 filings disclose insider transactions; a sale of this size by the executive chair is noteworthy.

Company-level read

Ticker impact

$SNPSBearishMedium confidence
Context

Executive Chair Aart de Geus sold $21.4M of Synopsys shares via a 10b5‑1 plan, reducing his stake to 120,443 shares.

Expected impact

Possible modest downside pressure over the next few days.

Evidence & confidence

A $21M sale by the company's top executive is material and disclosed first via Form 4; markets often react to sizable insider disposals.

Market effects

May raise questions about Synopsys' growth outlook within the EDA sector.

Limited to U.S. tech equities; no broader regional effect.

Minimal global impact beyond Synopsys investors.

Counterpoint

The sale is pre‑arranged under a 10b5‑1 plan and may not reflect current sentiment.

Key entities

  • Synopsys Inc.

    U.S. listed provider of electronic design automation software (ticker SNPS).

  • Aart de Geus

    Executive Chair of Synopsys, filing a $21.4M share sale.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$SNPSMed

SNPS Upgraded by Morgan Stanley -- Price Target Maintained at $5

Morgan Stanley upgraded Synopsys (SNPS) to Overweight, maintaining a $500 price target. The stock is trading at $396.11, which is 39.9% undervalued according to its GF Value™ of $659.20. Synopsys has a GF Score™ of 88/100, indicating strong growth potential but concerns about valuation. Insider activity shows significant selling, with $40.7 million in sales over the last three months.

$SNPSMedAI 9/10

How to Play SNPS Stock as Layoffs Hit Synopsys

Synopsys (SNPS) reported Q3 FY2026 earnings with revenue of $2.48B, up 42.4% YoY, and EPS of $3.91, beating estimates. The company raised its full-year outlook. Analysts maintain 'Buy' ratings with price targets up to $633, citing long-term growth potential in semiconductor design.

$SNPSMedAI 8/10

Synopsys Falls as Strong Results Fail to Clear a High Bar

Synopsys (SNPS) shares fell 5.9% after reporting Q3 revenue of $2.48B and EPS of $3.91, both above guidance. The company raised full-year targets to $9.715B revenue and $15.07 EPS, but investors reacted negatively due to modest outlook increases, restructuring costs, and acquisition-related expenses. Insider sales and mixed hedge fund activity were also noted.